FDA cleared of accusations over special treatment of RU-486

NEW YORK A government report has found that the Food and Drug Administration did not provide special treatment in approving or overseeing the birth-control pill RU-486, Bloomberg reported.

The report, by the Government Accountability Office, found that the FDA approved and monitored the drug consistently with other products whose distribution is restricted.

More than 900,000 women in the United States have taken the drug, which New York-based Danco Laboratories markets as a non-surgical option for early abortion under the brand name Mifeprex. Its generic name is mifepristone.